TSHA

$4.33+5.87%

Taysha Gene Therapies, Inc.

Market Cap

$1.4B

Live price × SEC shares (Aug 11, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.40

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

257.2

TTM to Jun 2026 · revenue

P/B

3.6

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

N/M

TTM to Jun 2026 · negative EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	0	5,485	0	0	5,485
Research & development	25,745	24,952	33,809	38,636	123,142
Total operating expenses	34,024	33,785	43,486	47,349	158,644
Operating income	(34,024)	(28,300)	(43,486)	(47,349)	(153,159)
Interest expense	15.0	12.0	9.0	6.0	42.0
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(32,733)	(27,851)	(42,410)	(46,639)	(149,633)
EPS (basic) ($)	(0.09)		(0.12)	(0.13)	(0.41)
EPS (diluted) ($)	(0.09)		(0.12)	(0.13)	(0.41)
Weighted avg. shares (basic)	353,310		366,633	369,044
Weighted avg. shares (diluted)	353,310		366,633	369,044

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 11, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 23 more quarters, back to Dec 2019, with Tormere Pro.

Signals

purchases / sales, 90d

Short Volume

77%

W/W +13.5pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-07-10	2026-07-10	Nagendran Sukumar	Director & President and Head of R&D	Sale	200.0K	$6.24	$1.25M	936.4K	View
2026-04-10	2026-04-13	Nagendran Sukumar	Director & President and Head of R&D	Sale	200.0K	$4.46	$892K	1.14M	View